Diagnosis Of Breast Cancer Technology Articles & Analysis
6 articles found
Introduction For years, scientists have leveraged the brilliant potentialities of genetic science to explore how cells function and interact in living organisms. Among the numerous tools employed are "reporter systems," which use a visible marker to track gene expression, protein interactions, and other vital biological processes. One such system employs reporter lentiviral particles, using the ...
People living with frontotemporal dementia, or FTD, are commonly misdiagnosed with psychiatric disorders or Alzheimer’s disease and other causes of dementia, such as Parkinson’s disease and vascular dementia. While frontotemporal dementia and Alzheimer’s disease can both cause dementia, there are distinct differences in impacted regions of the brain and, consequently, ...
Alzheimer’s and Parkinson’s disease are both neurological diseases that cause progressive damage to the brain, resulting in a decline in neurocognitive function. While Parkinson’s disease is known for affecting movement and function and Alzheimer’s disease is known for affecting cognition, they are a bit more complex than that. Below, we provide an overview of ...
Humans are inherently social beings who thrive on making and maintaining social relationships. Connecting with and supporting one another forms deep bonds that make us feel seen, valued, and like we belong. These social interactions are not only important for our emotional well-being but also for our physical well-being-maybe even more so than originally thought. Loneliness, an increasingly ...
Summary Nanostics' clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked research institute in the Northeast US will now partner with Nanostics' by recruiting patients for the clinical validation study This partnership will ...
METAFORA is proud to announce that its first publication related to the use of its technology to diagnose a rare metabolic disease rapidly and efficientely has been accepted for publication in the reference journal, Annals of Neurology. The test is being commercialized under the name METAglut1 and was recently CE marked. It is available in France through the CERBA network of clinical testing ...